3 Out-of-Favor Stocks That Concern UsThe past year hasn't been kind to the stocks featured in this article. Each has tumbled to their lowest points in 12 months, leaving investors to decide whet...
CONMED, Bruker, Waters Corporation, Avantor, and Bio-Techne Stocks Trade Down, What You Need To KnowWhat Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as in...
3 Mid-Cap Stocks with Open QuestionsMid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. Howe...
Winners And Losers Of Q4: Waters Corporation (NYSE:WAT) Vs The Rest Of The Research Tools & Consumables StocksQuarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
3 Cash-Producing Stocks Walking a Fine LineA company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Not...
3 Reasons to Sell WAT and 1 Stock to Buy InsteadSince September 2025, Waters Corporation has been in a holding pattern, posting a small return of 3.8% while floating around $311.11. Is there a buying oppor...
3 Reasons to Avoid WAT and 1 Stock to Buy InsteadWaters Corporation trades at $306.57 per share and has stayed right on track with the overall market, gaining 5.7% over the last six months. At the same time...
1 S&P 500 Stock on Our Buy List and 2 We IgnoreThe S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability.
But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Danaher Corporation (DHR): Navigating the Bioprocessing Thaw and the Masimo PivotAs of February 17, 2026, Danaher Corporation (
NYSE: DHR) finds itself at a pivotal juncture in its multi-decade evolution. Once the darling of the "compounding" investment community, the Washington, D.C.-based life sciences giant has recently seen its share price retreat from 2025 highs, currently trading down approximately 11% year-to-date. This volatility follows a complex narrative: [...]
WAT Q4 Deep Dive: Acquisition Integrates BD Biosciences, Margin Pressures Offset Revenue GrowthScientific instruments company Waters Corporation (
NYSE:WAT) met Wall Street’s revenue expectations in Q4 CY2025, with sales up 6.8% year on year to $932.4 million. The company expects next quarter’s revenue to be around $1.20 billion, coming in 64.5% above analysts’ estimates. Its non-GAAP profit of $4.53 per share was in line with analysts’ consensus estimates.
The Measurement Giant Reimagined: A Deep Dive into Waters Corporation (WAT) in 2026As of February 10, 2026, Waters Corporation (
NYSE: WAT) stands at the most significant crossroads in its nearly 70-year history. Long regarded as the gold standard in liquid chromatography and mass spectrometry, the Milford, Massachusetts-based company has recently transitioned from a specialized toolmaker into a multi-disciplinary life sciences juggernaut. With the closing of its massive [...]
Waters Corporation (NYSE:WAT) Reports Q4 CY2025 In Line With ExpectationsScientific instruments company Waters Corporation (
NYSE:WAT) met Wall Street’s revenue expectations in Q4 CY2025, with sales up 6.8% year on year to $932.4 million. The company expects next quarter’s revenue to be around $1.20 billion, coming in 64.5% above analysts’ estimates. Its non-GAAP profit of $4.53 per share was in line with analysts’ consensus estimates.
Pure-Play Pivot: Decoding Becton Dickinson’s (BDX) Q1 Results and the $17.5B Waters CombinationToday, February 9, 2026, marks a watershed moment for Becton, Dickinson and Company (
NYSE: BDX). The medical technology giant, commonly known as BD, has officially closed its transformative $17.5 billion combination with Waters Corporation (
NYSE: WAT), effectively spinning off its Biosciences and Diagnostic Solutions units to create a more streamlined "New BD." Simultaneously, the company [...]
1 Profitable Stock on Our Buy List and 2 We AvoidWhile profitability is essential, it doesn’t guarantee long-term success.
Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".
3 Mid-Cap Stocks We Steer Clear OfMany investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities.
However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with vast resources to agile upstarts eager to disrupt the status quo.
